Nakagami Y, Kishimoto T, Matsumoto K
Gan To Kagaku Ryoho. 1985 Oct;12(10):1968-74.
Cancer of the urinary bladder is a tumor with the highest frequency among urogenital cancers, and more-over, its recurrence rate is high. It is considered important and urgently necessary to conduct studies into the prevention of recurrence of this cancer. We have started a Study Group on Postoperative Maintenance Therapy for Bladder Tumor (Tokyo), and conducted group studies on the prevention of recurrence. Fundamental experiments have been performed, and the following results obtained. Antitumor effects of PSK in combination with CQ for bladder carcinoma were studied using male ACI rats. An established bladder carcinoma cell line, BC47 was transplanted into the backs of rats subcutaneously prior to the administration of PSK and CQ. Inhibitory effect on tumor growth and prolongation of survival period were examined. Although single-agent PSK or CQ both had inhibitory effects on transplanted tumors as well as on metastatic tumors in the lung, more remarkable effects were noticed as a result of combination treatment. Prolongation of lifespan using combination therapy was superior to that using single treatment and the rats of decrease in body weight was also lower. These results do not necessarily clarify the antitumor mechanisms, but the immune system, probably non-specifically, may take part in the mechanism judged from the accumulated results obtained from in vivo systems. We think that the combinational effects of these two drugs on general condition are probably originated from inhibition of tumor growth since the inhibition, prolongation of lifespan, change of body weight and so on were closely correlated with each other. However, the direct effect of these drugs may also be counted. The combination therapy of PSK and CQ seemed to be useful against rat bladder carcinoma, BC47. We therefore intend to proceed with group study trials of Postoperative Maintenance Therapy for Bladder Tumor.
膀胱癌是泌尿生殖系统癌症中发病率最高的肿瘤，而且其复发率很高。开展针对该癌症复发预防的研究被认为是重要且迫切必要的。我们成立了膀胱肿瘤术后维持治疗研究小组（东京），并进行了预防复发的分组研究。已经开展了基础实验，并取得了以下结果。使用雄性ACI大鼠研究了PSK与CQ联合对膀胱癌的抗肿瘤作用。在给予PSK和CQ之前，将已建立的膀胱癌细胞系BC47皮下移植到大鼠背部。检测对肿瘤生长的抑制作用和生存期的延长情况。尽管单药PSK或CQ对移植瘤以及肺转移瘤均有抑制作用，但联合治疗的效果更显著。联合治疗延长寿命的效果优于单药治疗，且体重减轻的大鼠也更少。这些结果不一定能阐明抗肿瘤机制，但从体内系统获得的累积结果判断，免疫系统可能非特异性地参与了该机制。我们认为这两种药物对一般状况的联合作用可能源于对肿瘤生长的抑制，因为抑制、寿命延长、体重变化等相互之间密切相关。然而，这些药物的直接作用也可能起作用。PSK和CQ的联合治疗似乎对大鼠膀胱癌BC47有效。因此，我们打算继续进行膀胱肿瘤术后维持治疗的分组研究试验。
